Cyclacel Pharmaceuticals, Inc.
CYCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.70 | -37.99 | 7.58 | -2.90 |
| FCF Yield | -1.07% | -3.15% | -1.16% | -0.22% |
| EV / EBITDA | -62.21 | -19.97 | -64.53 | -365.46 |
| Quality | ||||
| ROIC | 515.92% | -3,488.90% | -110.14% | -51.00% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.71 | 0.71 | 0.98 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 50.43% | 22.64% | -12.21% | -131.22% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | 0.13 | 0.66 | 1.61 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.07 |
| Cash Conversion Cycle | 2,011.74 | 2,548.92 | -29,211.41 | -13,072.09 |